Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Acadia Pharmaceuticals Inc shares valued at $82,728 were sold by Schneyer Mark C. on Sep 15 ’25. At $23.65 per share, Schneyer Mark C. sold 3,498 shares. The insider’s holdings dropped to 43,447 shares worth approximately $0.92 million following the completion of this transaction.
Also, GAROFALO ELIZABETH A. sold 1,600 shares, netting a total of over 41,560 in proceeds. Following the sale of shares at $25.98 each, the insider now holds 25,382 shares.
Before that, Schneyer Mark C. had sold 22,000 shares from its account. In a trade valued at $554,024, the EVP, CHIEF FINANCIAL OFFICER traded Acadia Pharmaceuticals Inc shares for $25.18 each. Upon closing the transaction, the insider’s holdings decreased to 22,000 shares, worth approximately $0.85 million.
As published in a research note from Deutsche Bank on May 21, 2025, Acadia Pharmaceuticals Inc [ACAD] has been rated up from a Hold to a Buy and the price target has been revised to $35. Analysts at Deutsche Bank started covering the stock with ‘”a Hold”‘ outlook in a report released in mid February. As of January 03, 2025, Guggenheim has decreased its “Buy” rating to a “Neutral” for ACAD.
Analyzing ACAD Stock Performance
On last trading session, Acadia Pharmaceuticals Inc [NASDAQ: ACAD] plunged -9.92% to $21.26. The stock’s lowest price that day was $20.02, but it reached a high of $21.86 in the same session. During the last five days, there has been a drop of approximately -12.15%. Over the course of the year, Acadia Pharmaceuticals Inc shares have jumped approximately 28.61%. Shares of the company reached a 52-week high of $26.65 on 08/28/25 and a 52-week low of $13.40 on 04/09/25.
Support And Resistance Levels for Acadia Pharmaceuticals Inc (ACAD)
According to the 24-hour chart, there is a support level at 20.23, which, if violated, would cause prices to drop to 19.21. In the upper region, resistance lies at 22.07. The next price resistance is at 22.89. RSI (Relative Strength Index) is 30.57 on the 14-day chart, showing neutral technical sentiment.
Is Acadia Pharmaceuticals Inc subject to short interest?
Stocks of Acadia Pharmaceuticals Inc saw a sharp steep in short interest on 2025-08-29 dropping by -1.75 million shares to 9.28 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 11.03 million shares. A decline of -18.89% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.67 of the overall float, the days-to-cover ratio (short ratio) decline to 4.67.
Which companies own the most shares of Acadia Pharmaceuticals Inc (ACAD)?
In terms of Acadia Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 30 in the next 12 months, up nearly 27.12% from the previous closing price of $23.6. Analysts anticipate Acadia Pharmaceuticals Inc stock to reach 39 by 2025, with the lowest price target being 22. In spite of this, 16 analysts ranked Acadia Pharmaceuticals Inc stock as Buy at the end of 2025. On August 07, 2024, Morgan Stanley assigned a price target of “an Equal-weight” to the stock and downgraded coverage with a $20.
